Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Proof-of-concept Study Evaluating Efficacy and Safety of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis Who Are Inadequate Responders or Intolerant to Topical Corticosteroids
Conditions
Interventions
Placebo
Rilzabrutinib
Locations
31
United States
Antelope Valley Clinical Trials Site Number : 8400001
Northridge, California, United States
Asthma and Allergy Associates, PC Site Number : 8400008
Colorado Springs, Colorado, United States
Florida International Research Center Site Number : 8400002
Miami, Florida, United States
Skin Sciences, PLLC Site Number : 8400005
Louisville, Kentucky, United States
DS Research of Kentucky, LLC Site Number : 8400004
Louisville, Kentucky, United States
Integrative Skin Care of MS/SKYCRNG Site Number : 8400011
Ridgeland, Mississippi, United States
Start Date
September 9, 2021
Primary Completion Date
June 23, 2023
Completion Date
June 23, 2023
Last Updated
June 21, 2024
NCT07262983
NCT06389136
NCT06342713
NCT07290803
NCT07223697
NCT07265479
Lead Sponsor
Sanofi
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions